Cancer - Prostate(구연) (NP-062) 조직검사 Gleason 7 전립선암에서 upgrading이 근치적 전립선암적출술 후 생화학재발에 미치는 영향 서울특별시립 보라매병원 비뇨기과 안치현, 유상준, 박주현, 조성용, 조민철, 손환철, 정현 Purpose · To investigate the impact of pathologic upgrading of Gleason score (GS) 7 prostate cancer on the risk of the biochemical recurrence after radical prostatectomy Materials and methods · The prospectively collected prostate cancer records of 1678 patients with postoperative GS 7 prostate cancer without lymph node metastasis were reviewed retrospectively via two databases. · The patients were categorized into four groups depending on pathologic upgrading; upgraded GS 3+4, non-upgraded GS 3+4, upgraded GS 4+3, and non-upgraded GS 4+3. · Kaplan-Meier multivariate model were employed to examine the influence of pathologic upgrading of GS 7 prostate cancer on the risk of biochemical recurrence. Results · The mean age of the patients was significantly higher in the non-upgraded GS 4+3 group than other groups, whereas the mean prostate-specific antigen (PSA) level was lower in the upgraded GS 3+4 group than other groups. · Pathologic findings, such as extracapsular extension, seminal vesical invasion, and the surgical margin rate were different from each other group. · Five-year biochemical recurrence-free survival rate was 85%, 73%, 69%, and 60% in upgraded GS 3+4 group, non-upgraded GS 3+4 group, upgraded GS 4+3 group and non-upgraded GS 4+3, respectively. · There was no significant difference in the two middle patient groups; i.e., the non-upgraded GS 3+4 group and the upgraded GS 4+3 group (Log-rank test, p-value = 0.259). Conclusion · The information on pathologic upgrading in the biopsy reports of patients could help to provide more-detailed analysis for the biochemical recurrence of GS 7 prostate cancer. keywords : biochemical recurrence, pathologic upgrading, prostate cancer